Introduction
============

Osteoarthritis (OA) is a disease that is induced through several complex mechanisms, including the progressive erosion of articular cartilage, proteoglycan (PG) degradation and the disruption of the collagen network. It is the most common form of arthritis, and is a major cause of morbidity, limitations in activity, physical disability, excessive health care utilization and a reduced health-related quality of life, particularly in individuals aged ≥45 years ([@b1-etm-06-01-0125]). Treatments for OA are widely perceived as an unmet medical requirement. Until recently, there has been no specific remedy for the disease, despite the availability of supplements, such as chondroitin sulfate, and the wide range of effective analgesics and non-steroidal anti-inflammatory drugs (NSAIDs) that are used as treatments for OA. However, the pharmacological management of OA has targeted the symptoms of the disease, rather than the underlying causes ([@b2-etm-06-01-0125],[@b3-etm-06-01-0125]). Thus, there have been efforts to develop drugs that reverse, retard or stabilize the underlying pathological changes in OA, and thereby provide a long-term symptomatic relief.

At present, efforts are being focused on the discovery of drugs that affect multiple targets and levels of the disease network. A diverse range of studies have been performed in the emerging field of multi-target drug design ([@b4-etm-06-01-0125]--[@b7-etm-06-01-0125]). In addition, several studies have demonstrated that an improved method of treating OA may be to act on several targets simultaneously ([@b6-etm-06-01-0125],[@b8-etm-06-01-0125]). It has also been indicated that the substances used in traditional Chinese medicine (TCM) possess diverse biological activities, and their composition and pharmacodynamic action are improved when administered in conjunction, as opposed to individually ([@b9-etm-06-01-0125]). Therefore, the establishment of a comprehensive method that elucidates the multi-target capabilities of TCM is required for the development of new drugs to treat OA.

Taohong Siwu decoction (THSWD) is a TCM that was documented in 'YiZong JinJian' *(*compiled by Wu Qian in the Qing Dynasty), and has been prescribed to treat OA in China. It has been demonstrated that THSWD effectively inhibits the expression of matrix metalloproteinase (MMP)-1 in the articular cartilage of rats with knee osteoarthritis (KOA), modeled by Hulth's method, and reduces the levels of interleukin (IL)-l and IL-6 in the localized tissues of the KOA ([@b10-etm-06-01-0125],[@b11-etm-06-01-0125]). However, the underlying mechanisms of THSWD in the management of OA are poorly understood. With the progress that has been made in systems biology and bionetworks, network pharmacology has been used to study the functions of herbal formulations from a proteome or systematic level ([@b12-etm-06-01-0125]). Therefore, the aim of the present study was to elucidate the multi-target capabilities of the compounds in THSWD, based on the established methods of network pharmacology ([@b13-etm-06-01-0125],[@b14-etm-06-01-0125]). In addition, the study aimed to promote the understanding of the efficiency of THSWD, with regard to its application in OA, and to facilitate its modernization and global use.

Materials and methods
=====================

Construction and preparation of the compound ligand data-base
-------------------------------------------------------------

THSWD consists of six species of medicinal herbs: *Radix Rehmanniae Preparata* (Shudihuang), *Angelica sinensis* (Danggui), *Radix Paeoniae Alba* (Baishao), *Ligusticum chuanxiong* (Chuanxiong), *Prunus persica* (Taoren) and *Carthamus annuum* (Honghua). The compounds identified in the medicinal herbs of THSWD were determined from the Chinese Herbal Drug Database and the Handbook of the Chemical Constituents in Chinese Herb Original Plants ([@b15-etm-06-01-0125],[@b16-etm-06-01-0125]). Having excluded any duplicates, the total number of compounds was 206. The structures of the compounds were drawn using ISIS Draw, Version 2.5 (MDL Information Systems, Inc., San Leandro, CA, USA), and further optimized using Discovery Studio 2.0 (DS 2.0; Accelrys, Inc., San Diego, CA, USA), with a Merck molecular force field (MMFF).

The molecular descriptors of the ligand database were calculated in the quantitative structure-activity relationship (QSAR) module of DS 2.0 (Accelrys, Inc.), whilst the chemical space of the ligand database was constructed using 150 diversity descriptors, including 1D, 2D and 3D molecular descriptors. Principal component analysis (PCA) was then performed to map the chemical distribution of the ligands in chemical space.

Virtual docking screening
-------------------------

To highlight the THSWD components that were particularly likely to be active in the OA disease system, a docking protocol was performed, in order to identify any interactions with the common OA target enzymes. This was completed using DS 2.0 LigandFit (Accelrys, Inc.) ([@b7-etm-06-01-0125]).

The 3D crystal structures of the 15 protein targets associated with OA, as determined by the Therapeutic Targets Database (TTD; Bioinformatics and Drug Design group, National University of Singapore) and other literature sources ([@b17-etm-06-01-0125]--[@b20-etm-06-01-0125]), were obtained from the Research Collabatory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB; [Table I](#t1-etm-06-01-0125){ref-type="table"}), and uploaded into DS 2.0 (Accelrys, Inc.). The crystallographic water was removed, and hydrogen atoms were added. The inhibitor from the PDB file was used to define the active site, and the 206 compounds identified in THSWD were docked into the protein models. The ligand position and orientation were evaluated using DockScores, on the basis of the most favorable energy interactions between the ligand conformations and receptor proteins, as described previously ([@b21-etm-06-01-0125]). The 206 docked structures were thus sorted according to their DockScores.

Network construction and analysis
---------------------------------

Three networks were constructed for the purpose of the study. To create a candidate compound-candidate target (cC-cT) network, 242 drug/drug-like compounds associated with the 15 previously mentioned protein targets, were obtained from the TTD ([@b17-etm-06-01-0125]). Known compounds and their targets were used to generate a bipartite graph of compound-protein interactions, in which a compound and a protein were connected to each other if the protein was an action target of the compound. This gave rise to the cC-cT network. To create a potential compound-potential target (pC-pT) network, the top five of the DockScore-sorted THSWD compounds were selected as potential compounds ([@b18-etm-06-01-0125]). The pC-pT network was established by connecting the potential compounds to any corresponding potential targets that were associated with OA. The target-disease (T-D) network was constructed by connecting the 15 previously mentioned proteins to any associated diseases, as established from the TTD. Cytoscape 2.8.3 (Cytoscape Consortium; <http://www.cytoscape.org/>) was used in the construction of all the networks, as described previously ([@b22-etm-06-01-0125]). The compounds, targets and diseases were represented as nodes in the networks. The edges between the nodes represented intermolecular interactions. Data were analyzed using Cytoscape plugins.

Results
=======

Chemical distribution of the ligand database
--------------------------------------------

The global property map of the chemical space of the compounds in THSWD is depicted in [Fig. 1A](#f1-etm-06-01-0125){ref-type="fig"}, which demonstrates that the compounds possess a broad diversity in chemical space. In addition, several key molecular descriptors were statistically analyzed, and are listed in [Table II](#t2-etm-06-01-0125){ref-type="table"}. These results indicated that the majority of the THSWD compounds had desired drug-like properties, according to Lipinski's rule of five. To further confirm the drug-like properties of the THSWD compounds, the chemical space distribution of the known drug/drug-like compounds associated with the OA targets, as established from the TTD, were also charted. It was revealed that there were marked overlaps between these two molecular datasets in chemical space ([Fig. 1B](#f1-etm-06-01-0125){ref-type="fig"}), which indicated that THSWD contained drug-like and lead-like compounds.

Potential compound prediction
-----------------------------

The potential compound prediction was performed for the 15 proteins associated with OA using virtual screening. Docking revealed that the total number of potential compounds that exhibited desired interactions with the proteins was 38. Among these 38 compounds, 19 demonstrated potential biological activity with more than one target protein. These results indicated that THSWD contained a number of active compounds, which had the potential to lead to the broad-spectrum inhibition of a number of important target proteins.

C-T network construction and analysis results
---------------------------------------------

The cC-cT and pC-pT networks are demonstrated in [Figs. 2](#f2-etm-06-01-0125){ref-type="fig"} and [3](#f3-etm-06-01-0125){ref-type="fig"}, respectively. A histogram of the distribution of the number of targets correlated with each compound, and corresponding with the cC-cT and pC-pT networks, is demonstrated in [Fig. 4](#f4-etm-06-01-0125){ref-type="fig"}. The simple parameters of the cC-cT and pC-pT networks are exhibited in [Table III](#t3-etm-06-01-0125){ref-type="table"}. These results indicated that the majority of the candidate and potential compounds interacted with only one target protein; however, certain compounds were identified to be modulators of multiple targets.

T-D network construction and analysis results
---------------------------------------------

A total of 15 validated potential targets and the 69 diseases that were associated with them, as established from the TTD website, were used to construct the T-D network ([Table IV](#t4-etm-06-01-0125){ref-type="table"} and [Fig. 5](#f5-etm-06-01-0125){ref-type="fig"}). According to the US National National Library's Medical Subject Headings (<http://www.nlm.nih.gov/mesh>), the 69 diseases were classified into 20 groups. For example, OA, osteoporosis and rheumatoid arthritis were grouped as musculoskeletal diseases, while heart failure, myocardial infarction and ischemia reperfusion injuries were classified as cardiovascular diseases. This suggests that THSWD may demonstrate efficacy in targeting not only musculoskeletal diseases, but also neoplasms, nervous system diseases and cardiovascular diseases, amongst others.

Discussion
==========

The chemical space of the compounds in THSWD was defined by calculating a given set of descriptors for each molecule, and by using these values as coordinates in the multidimensional space. PCA was performed to map the multiple descriptor values into a 2D plane. This provided a novel method for demonstrating the established theory among chemists that similar compounds have similar properties ([@b23-etm-06-01-0125]). [Fig. 1A](#f1-etm-06-01-0125){ref-type="fig"} reveals that the compounds in THSWD possess a broad diversity in chemical space, which indicates that THSWD, as a natural combinatorial chemical library, has the potential to exhibit the desired interactions with a wider range of protein targets than the drug/drug-like compounds from the TTD. The marked overlap in [Fig. 1B](#f1-etm-06-01-0125){ref-type="fig"} suggests that THSWD is likely to contain active compounds that have the potential to exert synergistic therapeutic actions. The statistics of the drug-like properties listed in [Table II](#t2-etm-06-01-0125){ref-type="table"} show that the means of the molecular weight, the number of hydrogen bond donors, the number of hydrogen bond acceptors and AlogP are 321.59, 3.19, 5.97 and 1.71, respectively. According to Lipinski's rule of five ([@b24-etm-06-01-0125]), these results suggest that the majority of the compounds in THSWD have desired drug-like properties, and are suitable for screening lead compounds.

Using virtual docking screening, we demonstrated that THSWD contains certain potential promiscuous and combination drugs (50% for each); therefore, multiple active compounds in THSWD may simultaneously target several proteins associated with OA. In order to enhance our understanding of the functions of THSWD, the property profile of the potential compound-target interactions was compared with that of the candidate compound-target interactions, established from the TTD. The cC-cT network was generated by six connected components, with the candidate compounds in the outer circle of each component demonstrating fewer interactions with the target proteins. The mean number of candidate targets per candidate compound was 1.3. However, the pC-pT network consisted of 53 nodes (38 potential compounds and 15 potential targets) and 75 edges. The mean number of potential targets per potential compound was 2.0. Among the 38 potential compounds, nine were capable of acting on more than two targets. These potential compounds included 6-hydroxykaempferol-7-O-glucoside, folic acid, neocarthamin, safflor yellow A, ferulic acid, eugeniin, (Z)-5-hydroxy-3-butylidene-phthalide, carthamidin and amygdalin. Previous studies have revealed that the majority of these compounds exhibit biological activity against OA ([@b25-etm-06-01-0125]--[@b28-etm-06-01-0125]). A maximum of seven targets were correlated with one potential compound. Notably, the pC-pT network contained only one component, while the cC-cT network contained six. This indicated that the anti-OA action of THSWD was a result of holistic combinations attacking different targets, rather than a precise attack on a single target. Therapeutic polypharmacology involves the theory of treating multigenic, complex diseases by targeting multiple targets with one or more drugs, in order to effectively reset the regulatory network processes that are altered in the disease state ([@b29-etm-06-01-0125]). Therefore, therapeutic polypharmacology may explain why THSWD is effective in the treatment of OA.

In order to further understand the therapeutic polypharmacology of THSWD, a T-D network was contructed to study the correlation between the diseases and targets. As demonstrated in [Fig. 5](#f5-etm-06-01-0125){ref-type="fig"}, the majority of the diseases were classified as neoplasms and nervous system and cardiovascular diseases, in addition to musculoskeletal diseases. This suggests that THSWD is capable of exerting broad pharmacological effects. Amygdalin, for example, was indicated as a potential compound in THSWD. Amygdalin may treat OA by targeting heme oxygenase (HO)-1, an enzyme that has been associated with cardiovascular and musculoskeletal diseases, as well as neoplasms. In addition, it has been demonstrated that amygdalin has exhibited therapeutic potential in the prevention and treatment of atherosclerosis ([@b30-etm-06-01-0125]). Furthermore. amygdalin may significantly reduce plasma viscosity, prolong thromboplastin time and reduce fibrinogen levels, whilst exerting few effects on whole blood viscosity ([@b31-etm-06-01-0125]). Amygdalin has also been used for the treatment of asthma, tumors, bronchitis, emphysema, leprosy and diabetes ([@b32-etm-06-01-0125]). Clinical observations have indicated the efficacy of THSWD in internal medicine, gynecology, andriatrics, dermatology and ophthalmology ([@b33-etm-06-01-0125]). Therefore, taking into account the multi-component and multi-target patterns of THSWD, it is possible that THSWD may improve the efficiency of treatments for other diseases, aside from OA. It would be useful to determine the potential pharmacological effects of THSWD, in order to aid the development of new and effective therapeutic drugs from THSWD.

In conclusion, we have constructed a novel modeling system, by integrating chemical space, virtual screening and network pharmacology, to investigate the molecular mechanism of action of THSWD, with regard to its clinical efficacy against OA. Our results demonstrated that THSWD has an improved structural diversity, compared with the selected drug/drug-like compounds from the TTD, and contains several active compounds capable of targeting multiple OA-related proteins. Furthermore, the cC-cT and pC-pT networks revealed that THSWD possesses the properties of promiscuous and combination drugs for multi-target OA therapies. Moreover, the T-D network indicates that THSWD had therapeutic potential against diseases other than OA, such as cardiovascular diseases and neoplasms. This suggests that distinct diseases may be treated with the same TCM formula. As a whole, these results indicate that TCM formulations contain compounds with multi-target capabilities and broad pharmacological effects.
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###### 

Fifteen key protein targets associated with osteoarthritis.

  Protein    PDB code
  ---------- ----------
  ADAMTS-4   2RJP
  TNF-α      2AZ5
  iNOS       2Y37
  COX-1      3NT1
  COX-2      3N8X
  MMP-1      966C
  MMP-3      1C3I
  MMP-8      1ZS0
  MMP-9      1GKC
  MMP-12     3RTS
  MMP-13     3I7I
  VDR        1DB1
  PPARγ      2VSR
  CDK2       3PXY
  HO-1       3TGM

PDB, Protein Data Bank; ADAMTS-4, aggrecanase-1; TNF-α, tumor necrosis factor-α; iNOS, inducible nitric oxide synthase; COX, cyclooxygenase; MMP, matrix metalloproteinase; VDR, vitamin D nuclear receptor; PPARγ, peroxisome proliferator activated receptor-γ, CDK2, cyclin-dependent kinase-2; HO-1, heme oxygenase.

###### 

Mean, standard deviation, minimum and maximum values for the key variables of the compounds in Taohong Siwu decoction.

  Variable                    Mean      SD        Minimum   Maximum
  --------------------------- --------- --------- --------- ----------
  Molecular weight            321.59    180.74    59.11     938.66
  No. of hydrogen acceptors   5.97      5.64      0.00      26.00
  No. of hydrogen donors      3.19      3.60      0.00      17.00
  ALogP                       1.71      3.62      −9.55     13.60
  Molecular volume            219.39    111.99    53.16     538.85
  Wiener index                2179.23   3322.42   9.00      18291.00
  Zagreb index                115.26    71.47     12.00     368.00

SD, standard deviation.

###### 

Simple parameters of the (cC-cT) and (pC-pT) networks.

  Simple parameters            pC-pT network   cC-cT network
  ---------------------------- --------------- ---------------
  Connected components         1               6
  Network density              0.054           0.010
  Network heterogeneity        0.636           2.976
  Network centralization       0.083           0.382
  Characteristic path length   4.576           3.800
  Average no. neighbors        2.830           2.488
  Shortest paths               2756 (100%)     47636 (71%)

pC-pT, potential compound-potential target; cC-cT, candidate compound-candidate target.

###### 

Sixty-nine diseases correlated with the 15 potential target proteins.

  Index   Disease
  ------- ----------------------------------------
  D1      Abdominal aortic aneurysm
  D2      Acute lymphoblastic leukemia (ALL)
  D3      Acute myeloid leukemia (AML)
  D4      Adenomatous polyposis
  D5      ACTH-secreting pituitary tumors
  D6      Advanced lung cancer
  D7      Advanced solid tumors
  D8      Alzheimer's disease
  D9      Arthritis
  D10     Asthma
  D11     Atherosclerosis
  D12     Autoimmune diseases
  D13     B-cell malignancies
  D14     Behcet's disease
  D15     Bladder cancer
  D16     Brain cancer
  D17     Breast cancer
  D18     Carcinoma *in situ*, unspecified
  D19     Carpal tunnel syndrome
  D20     Chondrosarcoma
  D21     Chronic lymphocytic leukemia (CLL)
  D22     Chronic myeloid leukemia
  D23     Colorectal cancer
  D24     Crohn's disease
  D25     Diabetes mellitus
  D26     Dysmenorrhea, unspecified
  D27     Emphysema
  D28     Endometriosis
  D29     Gastro-intestinal ulcers
  D30     Genitourinary tumors
  D31     Gestational hypertension
  D32     Guillain-Barré syndrome
  D33     Heart failure
  D34     Hepatocellular carcinoma
  D35     Hormone-refractory prostate cancer
  D36     Hyperimmunoglobulinemia D
  D37     Inflammation
  D38     Inflammatory bowel disease
  D39     Insulin resistance
  D40     Ischemia reperfusion injuries
  D41     Ischemic heart disease
  D42     Kaposi's sarcoma
  D43     Lung cancer
  D44     Meningioma
  D45     Multiple sclerosis
  D46     Myocardial infarction
  D47     Nasopharyngeal cancer (NPC)
  D48     Neonatal hyperbilirubinemia, jaundice
  D49     Non-Hodgkin's lymphoma
  D50     Noninsulin-dependent diabetes mellitus
  D51     Non-small cell lung cancer
  D52     Obesity
  D53     Osteoarthritis
  D54     Osteoporosis, unspecified
  D55     Ovarian cancer
  D56     Pain, unspecified
  D57     Pancreatic cancer
  D58     Pathological angiogenesis
  D59     Peutz-Jeghers syndrome
  D60     Prostate cancer
  D61     Psoriasis
  D62     Renal cell carcinoma
  D63     Rheumatic diseases
  D64     Rheumatoid arthritis, unspecified
  D65     Squamous cell carcinoma
  D66     Stroke
  D67     Testicular cancer
  D68     Thyroid follicular carcinoma
  D69     Ulcerative colitis

ACTH, Adrenocorticotrophic hormone.
